Patents by Inventor Martin K. Safo
Martin K. Safo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220340531Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).Type: ApplicationFiled: June 22, 2022Publication date: October 27, 2022Inventors: Martin K. SAFO, Yan ZHANG, Piyusha Pradeep PAGARE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK
-
Patent number: 11458144Abstract: Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased O2 affinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.Type: GrantFiled: December 23, 2021Date of Patent: October 4, 2022Assignees: KING ABDULAZIZ UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA, VIRGINIA COMMONWEALTH UNIVERSITYInventors: Moustafa E. El-Araby, Abdelsatter M. Omar, Osheiza Abdulmalik, Martin K. Safo
-
Patent number: 11401241Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).Type: GrantFiled: March 18, 2019Date of Patent: August 2, 2022Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Martin K. Safo, Yan Zhang, Piyusha Pradeep Pagare, Guoyan Xu, Mohini Ghatge, Jurgen Venitz, Osheiza Abdulmalik
-
Patent number: 11325885Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: GrantFiled: August 19, 2021Date of Patent: May 10, 2022Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
-
Patent number: 11319292Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.Type: GrantFiled: September 7, 2021Date of Patent: May 3, 2022Assignees: KING ABDULAZIZ UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITYInventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
-
Patent number: 11312694Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: GrantFiled: September 24, 2021Date of Patent: April 26, 2022Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Martin K. Safo, Radwan S. Elhaggar, Tamer M. Abdelghany, Mostafa H. Ahmed
-
Patent number: 11312680Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: GrantFiled: August 19, 2021Date of Patent: April 26, 2022Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
-
Publication number: 20220033368Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: ApplicationFiled: September 24, 2021Publication date: February 3, 2022Applicant: King Abdulaziz UniversityInventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Martin K. SAFO, Radwan S. ELHAGGAR, Tamer M. ABDELGHANY, Mostafa H. AHMED
-
Publication number: 20220009896Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: ApplicationFiled: September 24, 2021Publication date: January 13, 2022Applicant: King Abdulaziz UniversityInventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Martin K. SAFO, Radwan S. ELHAGGAR, Tamer M. ABDELGHANY, Mostafa H. AHMED
-
Patent number: 11214537Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: GrantFiled: July 16, 2021Date of Patent: January 4, 2022Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
-
Patent number: 11214556Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: GrantFiled: September 24, 2021Date of Patent: January 4, 2022Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Martin K. Safo, Radwan S. Elhaggar, Tamer M. Abdelghany, Mostafa H. Ahmed
-
Publication number: 20210403434Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.Type: ApplicationFiled: September 7, 2021Publication date: December 30, 2021Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
-
Publication number: 20210395187Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: ApplicationFiled: August 19, 2021Publication date: December 23, 2021Applicant: King Abdulaziz UniversityInventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
-
Publication number: 20210380526Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: ApplicationFiled: August 19, 2021Publication date: December 9, 2021Applicant: King Abdulaziz UniversityInventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
-
Publication number: 20210340097Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: ApplicationFiled: July 16, 2021Publication date: November 4, 2021Applicant: King Abdulaziz UniversityInventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
-
Publication number: 20210340109Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.Type: ApplicationFiled: October 7, 2020Publication date: November 4, 2021Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
-
Patent number: 11155528Abstract: A compound of formula (I), wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.Type: GrantFiled: October 25, 2019Date of Patent: October 26, 2021Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Martin K. Safo, Radwan S. Elhaggar, Tamer M. Abdelghany, Mostafa H. Ahmed
-
Patent number: 11149012Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.Type: GrantFiled: October 7, 2020Date of Patent: October 19, 2021Assignees: King Abdulaziz University, Virginia Commonwealth UniversityInventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
-
Patent number: 11142493Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: GrantFiled: June 23, 2021Date of Patent: October 12, 2021Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
-
Patent number: 11136288Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.Type: GrantFiled: March 4, 2021Date of Patent: October 5, 2021Assignee: King Abdulaziz UniversityInventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed